Global Accelerator for Paediatric Formulations Network (GAP-f)

Global Accelerator for Paediatric Formulations Network (GAP-f)

GettyImages
© Credits

About us

GAP-f is a WHO Network hosted within the Research for Health Department in the Science Division and was created to respond to the persistent paediatric treatment gap.

Following the resolution at the 69th World Health Assembly on promoting innovation and access to quality, safe, efficacious, and affordable medicines for children, GAP-f was conceived to build on and formalize the model developed within the HIV community—providing a sustainable mechanism to accelerate the development and availability of safer, more effective paediatric formulations.

In 2024, Member States adopted a WHA resolution on Accelerating progress towards reducing maternal, newborn, and child mortality to achieve Sustainable Development Goal targets 3.1 and 3.2. While addressing the broader maternal and child health agenda, the resolution calls for renewed investment in developing and introducing better medicines for children, and recognizes GAP-f as a key collaboration platform. This not only reaffirms GAP-f’s mission but also expands its mandate, highlighting the importance of deeper engagement with Member States.

At GAP-f, children are at the top of our agenda. While significant gains in child health have been achieved—with six million fewer children under five dying in 2016 than in 1990—urgent action is still needed to meet the UN Sustainable Development Goals (SDGs), particularly SDG 3, which aims to ensure healthy lives and promote well-being for all at all ages, including the target to achieve Universal Health Coverage by 2030.

 

News

Documents

All →
Transforming the paediatric medicines ecosystem: strategic roadmap 2025–2030
This third phase of GAP-f’s strategy (2025-2030) focuses on strengthening the global ecosystem for paediatric medicines. With a streamlined approach and...
Accelerating research, development and access to paediatric medicines: Global accelerator for paediatric formulations (‎GAP-f)‎ progress report 2022-2024
The GAP-f Phase 2 Progress Report highlights the network’s achievements and milestones from 2022 to 2024, providing a transparent overview of its impact....
Shaping the global innovation and access landscape for better paediatric medicines: Global accelerator for paediatric formulations 2022–2024 strategy
The Global Accelerator for Paediatric Formulations Strategy (GAP-f) 2022–2024 strategy builds from the work undertaken to date by the network of leading...

 

Publications

All →
Transforming the paediatric medicines ecosystem: strategic roadmap 2025–2030

This third phase of GAP-f’s strategy (2025-2030) focuses on strengthening the global ecosystem for paediatric medicines. With a streamlined approach...

Accelerating the development of priority formulations for antibiotic use in children : target product profiles for paediatric formulations of priority antibiotics azithromycin and nitrofurantoin

This document summarizes proceedings and outcomes of a technical consultation designed to develop target product profiles for three priority antibiotics...

Accelerating optimal approval of priority formulations for antibiotic use in children: meetings report, 7 December 2023 and 19-20 March 2024

On 24 March 2023, WHO launched the first-ever list of priority paediatric formulations for antibiotics, addressing critical gaps in age-appropriate treatments...

Paediatric DTG implementation considerations for national programmes

In mid-2021, national HIV programmes began to transition treatment for children living with HIV to dolutegravir (DTG) 10 mg scored, dispersible tablets,...

Newsletter

Subscribe to our newsletter and other updates here.

Events

All →

GAP-f Secretariat

John Reeder

Director

Martina Penazzato

Technical lead

Email: penazzatom@who.int

Asma Hafiz

Project Manager

Email: ahafiz@who.int

Contact

For more information email: